NASDAQ:RGNX
REGENXBIO Inc.
REGENXBIO Inc.'s revenue grew 104.5% in fiscal 2025 to $170.4M while operating margin rose to −94.6%. Free cash flow was −$126.4M, −74.1% of revenue, and the diluted share count rose 4.2%.Summary generated from REGENXBIO Inc.'s SEC filings. Latest annual report filed Mar 5, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$170.4M
Revenue growth+104.5%
Revenue, 5-yr CAGR+2.0%
Gross marginn/a
Operating margin−94.6%
Net margin−113.8%
ROICn/a
Return on equity−107.0%
Debt / equityn/a
Free cash flow−$126.4M
FCF margin−74.1%
Share count change+4.2%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 470 | 113 | 90 | 83 | 170 |
| Operating income | 160 | −263 | −268 | −233 | −161 |
| Net income | 128 | −280 | −263 | −227 | −194 |
| Free cash flow | 135 | −238 | −228 | −176 | −126 |
Recent filings
- 8-KEntry into a material agreement
Sep 23, 2026 - 4Insider transaction report
Sep 3, 2026 - 4Insider transaction report
Sep 3, 2026 - 8-KDirector or officer change
Aug 25, 2026 - 8-KRegulation FD disclosure
Aug 24, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 6, 2026 - 8-KResults of operations and financial condition
Aug 6, 2026 - 8-KOther events
Jul 20, 2026